News

Luye Pharma Receives U.S. FDA Clearance to Initiate Clinical Trials for Its Novel Antidepressant LY03021

Shanghai, November 17, 2026 — Luye Pharma Group today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for LY03021, a next-generation central nervous system (CNS) drug candidate developed by the company and intended ...
November 17,2026

Luye Pharma Announces Renewed Inclusion of Its Innovative Antidepressant Ruoxinlin® in China’s 2026 National Reimbursement Drug List

Shanghai, November 15, 2026 — Luye Pharma Group today announced that it has successfully renewed the coverage of Ruoxinlin® (toludesvenlafaxine hydrochloride sustained-release tablets), a Class 1 innovative drug in China for the treatment of major depressive disorder (MDD), by ...
November 15,2026
31
2026-08
Luye Pharma Announces 2026 Interim Results
05
2026-08
Luye Pharma Announces Successful Completion of a U.S. Bridging Clinical Trial of Its Innovative Drug LY03015 (VMAT2 Inhibitor/Sigma-1R Agonist)
16
2026-06
Luye Pharma Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China
20
2026-04
Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
15
2026-04
Luye Pharma Announces First Subject Enrolled in China Phase Ⅱ Clinical Trial of LY03017 (5-HT2AR/5-HT2CR) for Alzheimer’s Disease-related Psychosis
08
2026-04
First Subject Enrolled in Phase Ⅱ Clinical Trial of Luye Pharma’s TAAR1/5-HT2CR-targeted Investigational Drug for Treating Schizophrenia
01
2026-04
Luye Pharma Announces 2025 Financial Results
13
2026-03
Luye Pharma Forms Strategic Partnership with Sinopharm Group and Sinopharm CNCM to Commercialize Mimeixin® and Other Products
08
2026-01
NMPA Accepts the NDA for Luye Pharma’s Ruoxinlin® for the New Indication of Generalized Anxiety Disorder
24
2025-12
Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Injectable Antipsychotics in the Chinese Mainland
1
2
3
4
5
News
Luye Pharma Receives U.S. FDA Clearance to Initiate Clinical Trials for Its Novel ...
Shanghai, November 17, 2026 — Luye Pharma Group today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for LY03021, a next-generation central nervous system ...

November 17,2026
Luye Pharma Announces Renewed Inclusion of Its Innovative Antidepressant Ruoxinlin® in ...
Shanghai, November 15, 2026 — Luye Pharma Group today announced that it has successfully renewed the coverage of Ruoxinlin® (toludesvenlafaxine hydrochloride sustained-release tablets), a Class 1 innovative drug in ...

November 15,2026
08-31
2026
Luye Pharma Announces 2026 Interim Results
08-05
2026
Luye Pharma Announces Successful Completion of a U.S. Bridging Clinical Trial of Its Innovative Drug LY03015 (VMAT2 Inhibitor/Sigma-1R Agonist)
06-16
2026
Luye Pharma Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China
04-20
2026
Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
04-15
2026
Luye Pharma Announces First Subject Enrolled in China Phase Ⅱ Clinical Trial of LY03017 (5-HT2AR/5-HT2CR) for Alzheimer’s Disease-related Psychosis
04-08
2026
First Subject Enrolled in Phase Ⅱ Clinical Trial of Luye Pharma’s TAAR1/5-HT2CR-targeted Investigational Drug for Treating Schizophrenia
04-01
2026
Luye Pharma Announces 2025 Financial Results
03-13
2026
Luye Pharma Forms Strategic Partnership with Sinopharm Group and Sinopharm CNCM to Commercialize Mimeixin® and Other Products
01-08
2026
NMPA Accepts the NDA for Luye Pharma’s Ruoxinlin® for the New Indication of Generalized Anxiety Disorder
12-24
2025
Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Injectable Antipsychotics in the Chinese Mainland
1
2
3
4
5